Metastatic Colorectal Cancer | CO.20
Phase III Randomized Study of BMS-582664 in Combination with Cetuximab (Erbitux®) Versus Placebo in Combination with Cetuximab (Erbitux®) in Patients Previously Treated with Combination Chemotherapy for Metastatic Colorectal Carcinoma.
Schema
Summary
The CO.20 study is designed to compare the overall survival of patients with previously treated metastatic colorectal carcinoma treated with Brivanib in combination with Cetuximab compared with placebo in combination with Cetuximab. The key question is: Does the addition of an antiangiogenesis inhibitor to standard treatment with an EGFR inhibitor improve the survival of patients with advanced colorectal cancer resistant to all prior chemotherapy regimens?
